

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition

Evangelos Terpos, Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Alexandros Briasoulis, Aimilia D. Sklirou, Christos Markellos, Efthymia Skafida, Alkistis Papatheodoridi, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Vassiliki A. Iconomidou, Ioannis P. Trougkos and Meletios-Athanasios Dimopoulos

Table S1. Case-control comparison regarding baseline characteristics.

Variables	Patient cohort (<i>n</i> = 85); Median (IQR)	Control cohort (<i>n</i> = 75); Median (IQR)	<i>p</i> -Value
Age	68.04 (62-77)	65.51 (62-68)	0.12
BMI	26.89 (24-29)	26.88 (24-29)	0.47
Sex			
Male	52 (61.18%)	31 (41.33%)	0.012
Female	33 (38.82%)	44 (58.67%)	
Type of vaccine			
BNT162b2/mRNA1273	68 (80%)	56 (74.67%)	0.45
AZD1222	17 (20%)	19 (25.33%)	